Neurofibroma of the urinary bladder

Liang Cheng, Bernd W. Scheithauer, Bradley C. Leibovich, Dharamdas M. Ramnani, John C. Cheville, David G. Bostwick

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

BACKGROUND. Neurofibroma of the urinary bladder is rare. Only isolated case reports have appeared. Information regarding the long term follow-up of patients with neurofibroma is limited. METHODS. The authors studied 4 cases of neurofibroma of the bladder diagnosed at Mayo Clinic from 1965 through 1990. Immunostains for S-100 protein, neurofilament protein, epithelial membrane antigen (EMA), cytokeratin (CAM 5.2; AE 1/3), Type IV collagen, MIB- 1, and p53 protein were performed in all cases, as was Alcian blue at pH 2.5. The mean follow-up was 9.6 years (range, 2-18 years). RESULTS. The mean age at diagnosis was 17 years (range, 7-28 years); the male-to-female ratio was 1:1. All four patients exhibited physical stigmata of neurofibromatosis type 1. Clinical presentations included hematuria (one patient), irritative symptoms (two patients), and pelvic mass (one patient). Long term urinary complications included bladder atony (two patients), neurogenic bladder (one patient), and recurrent urinary tract infection with hematuria (one patient). Subsequently, two patients underwent partial cystectomy and one a complete cystectomy. Involvement of the bladder was generalized in all four cases. Three tumors were transmural, showing a diffuse and plexiform pattern of growth; in the fourth case, a superficial biopsy showed only diffuse submucosal growth with conspicuous pseudo-Meissnerian corpuscle formation. An Alcian blue positive, variably collagenized matrix was present in all cases. Tumor cells displayed immunoreactivity for S-100 protein and Type IV collagen in all cases. Neurofilament protein positive axons were evident in three cases; all other immunostains were negative. The mean MIB-1 labeling index was 3.2% (range, 0.9-7.3%). No malignant transformation was observed during a mean follow-up of 9.6 years. CONCLUSIONS. Neurofibroma of the bladder presents early in life, is of the plexiform type with a diffuse component, and usually occurs in the setting of generalized neurofibromatosis type 1 rather than as isolated visceral neurofibromatosis. Malignant transformation did not occur in any of these 4 patients during a mean follow-up time of 9.6 years.

Original languageEnglish
Pages (from-to)505-513
Number of pages9
JournalCancer
Volume86
Issue number3
DOIs
StatePublished - Aug 1 1999

Fingerprint

Neurofibroma
Urinary Bladder
Neurofilament Proteins
Alcian Blue
Neurofibromatosis 1
S100 Proteins
Cystectomy
Hematuria
Ki-67 Antigen
Christianity
Mucin-1
Neurogenic Urinary Bladder
Neurofibromatoses
Collagen Type III
Collagen Type IV
Growth
Urinary Tract Infections
Axons
Neoplasms
Biopsy

Keywords

  • Bladder
  • Immunohistochemistry
  • Malignant malformation
  • Neoplasms
  • Neurofibroma
  • Neurofibromatosis type 1
  • Soft tissue
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheng, L., Scheithauer, B. W., Leibovich, B. C., Ramnani, D. M., Cheville, J. C., & Bostwick, D. G. (1999). Neurofibroma of the urinary bladder. Cancer, 86(3), 505-513. https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<505::AID-CNCR20>3.0.CO;2-A

Neurofibroma of the urinary bladder. / Cheng, Liang; Scheithauer, Bernd W.; Leibovich, Bradley C.; Ramnani, Dharamdas M.; Cheville, John C.; Bostwick, David G.

In: Cancer, Vol. 86, No. 3, 01.08.1999, p. 505-513.

Research output: Contribution to journalArticle

Cheng, L, Scheithauer, BW, Leibovich, BC, Ramnani, DM, Cheville, JC & Bostwick, DG 1999, 'Neurofibroma of the urinary bladder', Cancer, vol. 86, no. 3, pp. 505-513. https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<505::AID-CNCR20>3.0.CO;2-A
Cheng L, Scheithauer BW, Leibovich BC, Ramnani DM, Cheville JC, Bostwick DG. Neurofibroma of the urinary bladder. Cancer. 1999 Aug 1;86(3):505-513. https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<505::AID-CNCR20>3.0.CO;2-A
Cheng, Liang ; Scheithauer, Bernd W. ; Leibovich, Bradley C. ; Ramnani, Dharamdas M. ; Cheville, John C. ; Bostwick, David G. / Neurofibroma of the urinary bladder. In: Cancer. 1999 ; Vol. 86, No. 3. pp. 505-513.
@article{1c9f2036a0b14587a28c1eb3083a2534,
title = "Neurofibroma of the urinary bladder",
abstract = "BACKGROUND. Neurofibroma of the urinary bladder is rare. Only isolated case reports have appeared. Information regarding the long term follow-up of patients with neurofibroma is limited. METHODS. The authors studied 4 cases of neurofibroma of the bladder diagnosed at Mayo Clinic from 1965 through 1990. Immunostains for S-100 protein, neurofilament protein, epithelial membrane antigen (EMA), cytokeratin (CAM 5.2; AE 1/3), Type IV collagen, MIB- 1, and p53 protein were performed in all cases, as was Alcian blue at pH 2.5. The mean follow-up was 9.6 years (range, 2-18 years). RESULTS. The mean age at diagnosis was 17 years (range, 7-28 years); the male-to-female ratio was 1:1. All four patients exhibited physical stigmata of neurofibromatosis type 1. Clinical presentations included hematuria (one patient), irritative symptoms (two patients), and pelvic mass (one patient). Long term urinary complications included bladder atony (two patients), neurogenic bladder (one patient), and recurrent urinary tract infection with hematuria (one patient). Subsequently, two patients underwent partial cystectomy and one a complete cystectomy. Involvement of the bladder was generalized in all four cases. Three tumors were transmural, showing a diffuse and plexiform pattern of growth; in the fourth case, a superficial biopsy showed only diffuse submucosal growth with conspicuous pseudo-Meissnerian corpuscle formation. An Alcian blue positive, variably collagenized matrix was present in all cases. Tumor cells displayed immunoreactivity for S-100 protein and Type IV collagen in all cases. Neurofilament protein positive axons were evident in three cases; all other immunostains were negative. The mean MIB-1 labeling index was 3.2{\%} (range, 0.9-7.3{\%}). No malignant transformation was observed during a mean follow-up of 9.6 years. CONCLUSIONS. Neurofibroma of the bladder presents early in life, is of the plexiform type with a diffuse component, and usually occurs in the setting of generalized neurofibromatosis type 1 rather than as isolated visceral neurofibromatosis. Malignant transformation did not occur in any of these 4 patients during a mean follow-up time of 9.6 years.",
keywords = "Bladder, Immunohistochemistry, Malignant malformation, Neoplasms, Neurofibroma, Neurofibromatosis type 1, Soft tissue, Tumor",
author = "Liang Cheng and Scheithauer, {Bernd W.} and Leibovich, {Bradley C.} and Ramnani, {Dharamdas M.} and Cheville, {John C.} and Bostwick, {David G.}",
year = "1999",
month = "8",
day = "1",
doi = "10.1002/(SICI)1097-0142(19990801)86:3<505::AID-CNCR20>3.0.CO;2-A",
language = "English",
volume = "86",
pages = "505--513",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Neurofibroma of the urinary bladder

AU - Cheng, Liang

AU - Scheithauer, Bernd W.

AU - Leibovich, Bradley C.

AU - Ramnani, Dharamdas M.

AU - Cheville, John C.

AU - Bostwick, David G.

PY - 1999/8/1

Y1 - 1999/8/1

N2 - BACKGROUND. Neurofibroma of the urinary bladder is rare. Only isolated case reports have appeared. Information regarding the long term follow-up of patients with neurofibroma is limited. METHODS. The authors studied 4 cases of neurofibroma of the bladder diagnosed at Mayo Clinic from 1965 through 1990. Immunostains for S-100 protein, neurofilament protein, epithelial membrane antigen (EMA), cytokeratin (CAM 5.2; AE 1/3), Type IV collagen, MIB- 1, and p53 protein were performed in all cases, as was Alcian blue at pH 2.5. The mean follow-up was 9.6 years (range, 2-18 years). RESULTS. The mean age at diagnosis was 17 years (range, 7-28 years); the male-to-female ratio was 1:1. All four patients exhibited physical stigmata of neurofibromatosis type 1. Clinical presentations included hematuria (one patient), irritative symptoms (two patients), and pelvic mass (one patient). Long term urinary complications included bladder atony (two patients), neurogenic bladder (one patient), and recurrent urinary tract infection with hematuria (one patient). Subsequently, two patients underwent partial cystectomy and one a complete cystectomy. Involvement of the bladder was generalized in all four cases. Three tumors were transmural, showing a diffuse and plexiform pattern of growth; in the fourth case, a superficial biopsy showed only diffuse submucosal growth with conspicuous pseudo-Meissnerian corpuscle formation. An Alcian blue positive, variably collagenized matrix was present in all cases. Tumor cells displayed immunoreactivity for S-100 protein and Type IV collagen in all cases. Neurofilament protein positive axons were evident in three cases; all other immunostains were negative. The mean MIB-1 labeling index was 3.2% (range, 0.9-7.3%). No malignant transformation was observed during a mean follow-up of 9.6 years. CONCLUSIONS. Neurofibroma of the bladder presents early in life, is of the plexiform type with a diffuse component, and usually occurs in the setting of generalized neurofibromatosis type 1 rather than as isolated visceral neurofibromatosis. Malignant transformation did not occur in any of these 4 patients during a mean follow-up time of 9.6 years.

AB - BACKGROUND. Neurofibroma of the urinary bladder is rare. Only isolated case reports have appeared. Information regarding the long term follow-up of patients with neurofibroma is limited. METHODS. The authors studied 4 cases of neurofibroma of the bladder diagnosed at Mayo Clinic from 1965 through 1990. Immunostains for S-100 protein, neurofilament protein, epithelial membrane antigen (EMA), cytokeratin (CAM 5.2; AE 1/3), Type IV collagen, MIB- 1, and p53 protein were performed in all cases, as was Alcian blue at pH 2.5. The mean follow-up was 9.6 years (range, 2-18 years). RESULTS. The mean age at diagnosis was 17 years (range, 7-28 years); the male-to-female ratio was 1:1. All four patients exhibited physical stigmata of neurofibromatosis type 1. Clinical presentations included hematuria (one patient), irritative symptoms (two patients), and pelvic mass (one patient). Long term urinary complications included bladder atony (two patients), neurogenic bladder (one patient), and recurrent urinary tract infection with hematuria (one patient). Subsequently, two patients underwent partial cystectomy and one a complete cystectomy. Involvement of the bladder was generalized in all four cases. Three tumors were transmural, showing a diffuse and plexiform pattern of growth; in the fourth case, a superficial biopsy showed only diffuse submucosal growth with conspicuous pseudo-Meissnerian corpuscle formation. An Alcian blue positive, variably collagenized matrix was present in all cases. Tumor cells displayed immunoreactivity for S-100 protein and Type IV collagen in all cases. Neurofilament protein positive axons were evident in three cases; all other immunostains were negative. The mean MIB-1 labeling index was 3.2% (range, 0.9-7.3%). No malignant transformation was observed during a mean follow-up of 9.6 years. CONCLUSIONS. Neurofibroma of the bladder presents early in life, is of the plexiform type with a diffuse component, and usually occurs in the setting of generalized neurofibromatosis type 1 rather than as isolated visceral neurofibromatosis. Malignant transformation did not occur in any of these 4 patients during a mean follow-up time of 9.6 years.

KW - Bladder

KW - Immunohistochemistry

KW - Malignant malformation

KW - Neoplasms

KW - Neurofibroma

KW - Neurofibromatosis type 1

KW - Soft tissue

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0033178797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033178797&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990801)86:3<505::AID-CNCR20>3.0.CO;2-A

DO - 10.1002/(SICI)1097-0142(19990801)86:3<505::AID-CNCR20>3.0.CO;2-A

M3 - Article

C2 - 10430260

AN - SCOPUS:0033178797

VL - 86

SP - 505

EP - 513

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -